Download Oligonucleotide-based therapeutics

Final Announcement
13th Symposium on Pharmacokinetics and Drug Metabolism
Oligonucleotide-based therapeutics
New challenges in evaluating pharmacokinetic, pharmacodynamic and
safety properties
March 16-17, 2015
Göteborg/Mölndal, Sweden
Main sponsor:
Cardiovascular and Metabolic Diseases R & D Mölndal
Swedish Academy of Pharmaceutical Sciences
The Section of Pharmacokinetics and Drug
Metabolism within the Swedish Pharmaceutical
Society is pleased to welcome you to the 13th
Symposium on Pharmacokinetics and Drug
Metabolism (previously known as the “Rosenön
meeting”). The aim of the Symposium series is to
highlight hot topics within the field.
The scientific applications of oligonucleotide based drugs
are rapidly increasing and have garnered tremendous
interest over the past two decades. Oligonucleotide based
drugs act at the level of messenger RNA (mRNA), either
by direct targeting of mRNA or regulatory microRNA.
Rather than modulating activity of specific proteins, these
approaches lead to altered levels of target proteins and are
independent of the structure of the protein, thus opening
up completely new opportunities for drug interventions.
However, oligonucleotide-based therapeutics carry
specific challenges concerning drug delivery, organ- and
cell uptake as well as pharmacokinetics and safety, which
are the topics of this meeting.
Who should attend?
This multidisciplinary conference will be of interest to
anyone engaged in drug discovery and development.
Expected participants include academic and industrial
scientists as well as regulatory assessors working on
DMPK, toxicology, pharmacodynamics or pharmaceutics.
We also encourage students to attend through a favorable
student fee.
The conference will cover the following areas:
✚✚ Introduction to oligonucleotide-based therapeutics
✚✚ Delivery, uptake and modeling of oligonucleotide drugs
✚✚ Regulation of ADME genes
✚✚ Safety aspects
✚✚ Regulatory aspects
Organizing committee
Tommy B. Andersson, AstraZeneca R&D, Sweden;
Siv Jönsson, Uppsala University, Sweden; Gustav Ahlin,
MPA, Sweden; Patrik J Andersson, AstraZeneca R&D,
Sweden; Eva Lundborg, AstraZeneca R&D, Sweden; Shalini
Andersson, AstraZeneca R&D, Sweden; Suzanne Iverson,
AstraZeneca R&D, Sweden; Axel Ståhlbom, MPA, Sweden;
Helena Sjöberg, AstraZeneca R&D, Sweden; Lilian WaltherJallow, Swedish Academy of Pharmaceutical Sciences,
Sweden.
Program
For detailed program please visit
www.lakemedelsakademin.se/oligo.
Confirmed speakers
Scott Henry, PhD, DABT, is Vice President of Non-Clinical
Development at Isis Pharmaceuticals, CA, USA.
Thomas Thum, MD, PhD, FESC, FAHA, is Professor and
specialist in Internal Medicine and Cardiology at Institute
for Molecular and Translational Therapeutic Strategies,
Medizinische Hochschule Hannover, Germany.
Robert Persson, PhD, is Senior Pharmacologist at Santaris
Pharma A/S, Denmark.
Sophie Callies (PharmD, PhD) is Principal Research
Scientist in the global Pharmacokinetics/Pharmacodynamics and Pharmacometrics department at Eli Lilly,
Paris, France.
Monika Sundqvist, PhD, is a Preclinical and Translational
PK & PKPD Scientist at AstraZeneca R&D Mölndal Sweden.
Morten Lindow, PhD, is Associate director (informatics)
at Santaris Pharma A/S and adjunct associate professor in
bioinformatics at the University of Copenhagen, Denmark.
Marino Zerial, PhD, is Director at the Max Planck Institute of
Molecular Cell biology and Genetic and Honorary Professor
at the Medical Faculty, University of Technology, Dresden,
Germany.
Bård Smedsrød, PhD, is Professor in Cell Biology and
Head of Vascular Biology Research Group, at Department of
Medical Biology, University of Tromsø, Norway and Founder
and CSO of D’Liver.
Magnus Ingelman-Sundberg, PhD, BScMed, is Professor,
Section Head and Vice Chairman at Molecular Toxicology
Department, Karolinska Institutet, Stockholm, Sweden.
Patrik Andersson, PhD, is a Project Toxicologist of
AstraZeneca and is currently spending a sabbatical period
at Regulus Therapeutics and ISIS Pharmaceuticals, CA, USA.
Camilla Svensson, PhD, is Non-Clinical Assessor of
Biologics at the Department of Clinical Trials and Special
Permissions, Medical Products Agency, Uppsala, Sweden.
General Information
Registration
Registration is done at www.lakemedelsakademin.se.
Before Febr 13 Beginning Febr 13
Industry
3000 SEK
3500 SEK
Academy
2000 SEK
2500 SEK
PhD Student/
1000 SEK
1500 SEK
Postdoc presenting a poster
All prices excl. VAT
The participation fee includes coffee lunch and dinner
March 16-17. A number of rooms are pre-booked at Gothia
Towers, www.gothiatowers.com on March 16-17, 2015. To
book a room please use the folllowing code ”LÄK150315”.
Rooms are available for booking until February 16, 2015.
All prices are excl. VAT.
Poster session
The program includes a poster session, to which all
delegates may apply. A number of accepted posters may be
selected for oral presentation. Please submit your poster
abstracts before February 16, 2015 by e-mail to jenny.
[email protected]. Please register as soon
as you have received information regarding acceptance of
your abstract.
Sponsors/Exhibitors
We invite you to become one of the sponsors/exhibitors
of the Rosenön Meeting 2014. To find information about
sponsoring and exhibition please visit our web site
www.lakemedelsakademin.se
Venue
The Rosenön Meeting takes place at hotel Gothia Towers
in Göteborg on March 16 and at AstraZeneca in Mölndal
on March 17. There will be a shuttle bus from the hotel
to AstraZeneca in the morning of March 17. The official
language of the meeting is English.
Cancellation Policy
For information about the cancellation policy, cancellation
insurance and VAT, please see our home page www.
lakemedelsakademin.se. Substitutes may however be made
at any time. Kindly forward the name of the substitute to
[email protected].
Please register at: www.lakemedelsakademin.se/oligo
B
Sverige
Porto betalt
Welcome to the 13th Symposium on
Pharmacokinetics and Drug Metabolism
– Oligonucleotide-based therapeutics
Please register at:
www.lakemedelsakademin.se/oligo
Box 1136, 111 81 Stockholm, Sweden